Saturday 17 October 2026 Export CELC’s income statement to Excel — free account

Celcuity, Inc.

In the quarter to June 2026, EPS fell 38.5%, free cash flow fell 53.3% and total debt rose 658.7%, each against the same quarter a year earlier.

56.16 4.14 −6.87%

Follow CELC

Alert me

Market cap: $3.0B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 327.56

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	2	1	—	1	—	2	—	1	—	—	—

Insider Ownership 26.50%

Capital & Financial Ratios $m

Market Cap 2,950.00

Revenue —

Net Income (226.48)

Free Cash Flow (192.28)

Net Debt (0.81)

Current Ratio 8.93

Debt/Equity (58.93)

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth (34.49%)

Next Y EPS Growth 53.80%

Next Y revenue growth —

Next 5Y EPS Growth 52.85%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	181	235	441	754
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	10	3	5	9
	191	245	466	776

	2023	2024	2025	Q'26
Payables	5	9	6	8
ST’ Debt	—	—	—	—
Other	—	—	—	—
	14	32	44	87

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	34.96%	53.75%	(9.08%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(55)	(55)	—	—	—
’25	(36)	(36)	(45)	(36)	(153)
’24	(17)	(18)	(21)	(28)	(83)
’23	(13)	(10)	(13)	(19)	(54)
’22	(6)	(11)	(9)	(9)	(36)
’21	(3)	(8)	(4)	(6)	(20)
’20	(2)	(2)	(2)	(2)	(7)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(55)	(56)	—	—	—
’25	(36)	(36)	(45)	(36)	(154)
’24	(17)	(18)	(21)	(28)	(84)
’23	(13)	(10)	(13)	(19)	(54)
’22	(6)	(11)	(9)	(10)	(36)
’21	(3)	(8)	(4)	(6)	(20)
’20	(2)	(2)	(2)	(2)	(7)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.97)	(1.44)	—	—	—
’25	(0.86)	(1.04)	(0.92)	(0.97)	(3.79)
’24	(0.64)	(0.62)	(0.70)	(0.85)	(2.83)
’23	(0.55)	(0.66)	(0.83)	(0.65)	(2.69)
’22	(0.53)	(0.67)	(0.75)	(0.69)	(2.64)
’21	(0.25)	(1.11)	(0.41)	(0.45)	(2.21)
’20	(0.22)	(0.21)	(0.24)	(0.25)	(0.92)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	11.10	13.16	8.91	4.03	9.26	4.81	8.39	11.51	7.58	Analyst estimates 2026–2028 Powerpack
	High	—	21.98	31.00	25.00	12.70	33.01	14.34	15.62	22.19	112.64
People
People	Employees	15	22	26	27	30	39	45	55	87	155
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(3)	(6)	(7)	(7)	(9)	(30)	(40)	(64)	(112)	(177)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(3)	(6)	(7)	(7)	(9)	(30)	(40)	(64)	(112)	(177)
	Depreciation	0	0	0	0	0	1	1	0	1	3
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(0.52)	(0.84)	(0.74)	(0.72)	(0.92)	(2.21)	(2.64)	(2.69)	(2.83)	(3.79)
	Cash flow	(0.46)	(0.66)	(0.60)	(0.59)	(0.70)	(1.52)	(2.34)	(2.27)	(2.12)	(3.28)
	Capex	(0.01)	(0.03)	(0.06)	(0.04)	(0.01)	(0.01)	(0.01)	0.00	(0.01)	(0.01)
	Free cash flow	(0.46)	(0.70)	(0.66)	(0.62)	(0.70)	(1.52)	(2.35)	(2.28)	(2.12)	(3.28)
	Book value	0.89	4.21	2.50	1.89	1.14	5.13	8.68	5.90	2.93	2.15
	Shares, m	6	7	10	10	10	13	15	24	39	47
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(3)	(5)	(6)	(6)	(7)	(20)	(36)	(54)	(83)	(153)
	Capex	0	0	(1)	0	0	0	0	0	0	0
	Free cash flow	(3)	(5)	(7)	(6)	(7)	(20)	(36)	(54)	(84)	(154)
Balance, $m
Balance, $m	Working capital	5	24	25	18	11	83	168	176	213	422
	Total debt	—	—	0	0	0	15	35	37	98	322
	Net debt	(6)	(24)	(25)	(19)	(12)	(70)	(134)	(144)	(137)	(120)
	Shareholders’ equity	6	31	25	19	12	69	134	140	116	101
Returns, %
Returns, %	ROA	(58.30)	(32.88)	(25.80)	(31.78)	(57.01)	(59.89)	(30.86)	(34.76)	(51.23)	(49.75)
	ROIC	0.00	(52.07)	(1,050.38)	(845.90)	(8,215.44)	0.00	(14,733.36)	0.00	0.00	0.00
	ROE	(62.30)	(33.79)	(26.37)	(32.97)	(61.12)	(73.63)	(39.88)	(46.63)	(87.54)	(163.80)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
XENE Xenon Pharmaceuticals Inc.	$3.3B	— (loss-making)	— (loss-making)	+100.70% (above 0%: growing)	n/m	−48.57% (below 0%: shrinking)	100.00%	0.00%	Compare
IDYA IDEAYA Biosciences, Inc.	$3.3B	— (loss-making)	— (loss-making)	+125.77% (above 0%: growing)	n/m	−41.09% (below 0%: shrinking)	100.00%	(1,380.73%)	Compare
CELC Celcuity, Inc.	$3.0B	— (loss-making)	—	—	n/m	−53.27% (below 0%: shrinking)	0.00%	0.00%
DNLI Denali Therapeutics Inc.	$2.9B	— (loss-making)	— (loss-making)	−89.74% (below 0%: shrinking)	n/m	−22.91% (below 0%: shrinking)	97.42%	(3,622.11%)	Compare
RCUS Arcus Biosciences, Inc.	$2.9B	— (loss-making)	— (loss-making)	−74.38% (below 0%: shrinking)	n/m	+10.53% (above 0%: growing)	100.00%	(234.15%)	Compare
ELVN Enliven Therapeutics, Inc.	$2.9B	— (loss-making)	—	—	n/m	−8.34% (below 0%: shrinking)	0.00%	0.00%	Compare
DYN Dyne Therapeutics, Inc.	$2.9B	— (loss-making)	—	—	n/m	−39.08% (below 0%: shrinking)	0.00%	0.00%	Compare
NRIX Nurix Therapeutics, Inc.	$2.7B	9.7×	— (loss-making)	+8,426.27% (above 0%: growing)	n/m	+1,122.10% (above 0%: growing)	100.00%	83.12%	Compare
ZLAB Zai Lab Limited Unsponsored ADR	$2.7B	— (loss-making)	— (loss-making)	−3.33% (below 0%: shrinking)	n/m	−84.42% (below 0%: shrinking)	54.70%	(71.95%)	Compare
Median of peers	$2.9B	—	—	+48.68%	—	−30.99%	98.71%	(35.97%)

All 614 Biotechnology stocks →

Celcuity, Inc. (CELC) key facts

Celcuity, Inc. (CELC) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CELC traded at $56.16, a market capitalization of $3.0 billion.
Return on equity was −163.8% and debt-to-equity -58.93.

Source: company filings (standardised) and stockrow calculations.